RecruitingPhase 2NCT06548204

Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial

Sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine

Enrollment

152 participants

Start Date

Jan 20, 2025

Study Type

INTERVENTIONAL

Conditions

ST-segment elevation myocardial infarction (STEMI)

Summary

The purpose of this study was to evaluate the efficacy and safety of fexofenadine hydrochloride on the basis of standard treatment after PCI in STEMI patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Fexofenadine Hydrochloride and Placebo for people with st-segment elevation myocardial infarction (stemi). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.